📢 One month left to apply for the ICARe 2026!
🗓️ Application deadline: June 21, 2026
📆 Course dates: October 10–18, 2026
📍 Les Pensières Center for Global Health, Annecy
Spots are limited: secure yours now and be part of the future of antibiotic research.
Info & application ➡️ www.icarecourse.org
We’re still here at #ESCMIDGlobal2026 ready to connect!
No booth? No problem. The conversations are what matter most, and we’re all in. If you’ve got ideas, insights, challenges, or something exciting to share: we’re all ears!
We are still around and would love to chat.
Let’s make it happen!
The weekend is almost here, time for a good book.
It’s been a while since we shared our community-built Phage reading list, so here’s what we’ve gathered so far.
Have a title we should add? We’d love to hear it.
Wishing you a relaxing, inspiring weekend
Big milestone in the fight against AMR 👏
Congrats BioVersys on the first patient, first visit in the Phase 3 BV100 trial — a key step toward new treatments for drug-resistant infections.
At INCATE, we know how vital this progress is.
➡️ Read more: ir.bioversys.com/news/biovers...
We heard you 👀 With the long weekend coming up, many couldn’t join Entrepreneurs Club #6 — so we’ve moved it!
📅 May 28 | 🕔5pm CEST
Join us for “What does it take to be an entrepreneur?” !
Save your spot ➡️ www.eventbrite.ch/e/entreprene...
#EntrepreneursClub #StartupLife
🚀 ESCMID Global is almost here!
No booth? No problem. INCATE will be in the heart of the action in Munich.
Meet our team — Peter Seiler, Ina-Kristin Behrens, Holger Zimmermann & Sina Gerbach. Got ideas or insights? Let’s talk.
📩 comms@incate.net
#ESCMIDglobal2026 #innovation #networking
🚀The Entrepreneurs Club is back!
Join our 6th edition as 3 expert speakers share what it really takes to be an entrepreneur—through real experiences, insights, and lessons learned.
Get inspired, gain practical tips, and hear fresh perspectives.
Save your spot ➡️ www.eventbrite.ch/e/entreprene...
INCATE had the pleasure of joining “Antibiotic Resistance: Ways out of the Crisis” in Basel, represented by Holger, Peter, and Valéry. From cutting-edge research at the Biozentrum to engaging discussions with the AntiResist network, the event highlighted collaborative efforts to tackle AMR.
#AMR
New paper dives into emerging perspectives that go beyond the usual narratives and highlight where innovation is most urgently needed.
Read paper ➡️ buff.ly/mh53wW9
Curious to hear your thoughts. What stands out most to you?
💥 Our March newsletter is out! 💥
- AMR Conference insights
- New INCATE milestones
- Educational opportunities
- ... and more!
Read all about it in INCATE's Newsletter ➡ 6s05i.r.sp1-brevo.net/mk/mr/sh/6rq...
Haven't subscribed yet?
Don't fall behind, subscribe here ➡ www.incate.net/newsletter/
New research in International Journal of Infectious Diseases explores a twist in cystic fibrosis infections: key pathogens may have fewer defenses against bacteriophages, opening the door to entirely new treatment strategies.
Read paper ➡️ www.ijidonline.com/article/S120...
#CysticFibrosis
Big step in antibiotic innovation: Basilea Pharmaceutica has dosed the first volunteer in its Phase 1 study of BAL2420
This novel antibiotic targets LptA.
🚀 A key milestone in the fight against antimicrobial resistance.
Read more ➡️ www.basilea.com#news_1594
#AMR #Antibiotics #Innovation
The PathoBlock Team is on the hunt for their next Life Science Manager!
Ready to be part of the fight against AMR? Or know someone who is?
Spread the word and help them find the perfect fit ➡️ www.linkedin.com/posts/incate...
📢 Applications for the Interdisciplinary Course on Antibiotics and Resistance (ICARe) are now open!
🗓️ Application deadline: June 21, 2026
📆 Course: October 10-18, 2026
📍 Les Pensières Center for Global Health, Annecy
Info & application ➡️ buff.ly/c9b45Lr
Awesome news to start the week!
The PROTON team from the @helmholtzhzi.bsky.social sky.social - an INCATE portfolio venture - has just won the concept phase of the Science4Life Venture Cup.
Read it here ➡️ www.helmholtz-hzi.de/en/media-cen...
#Startups #AntimicrobialResistance #Innovation
What if penicillin could be deadly again, even to “surviving” bacteria? Some bacteria don’t resist antibiotics… they wait them out. But what if that survival mode is actually their weak spot?
Are we underestimating the power of what we already have?
Read here ➡️
What if Phages are not an alternative to antibiotics but their best partner?
Phage–antibiotic combos are showing real promise against resistant infections.
But: how do we pick the right phage? Dose it? Scale something so personalized?
Read the Contagion_Live article ➡️
2 days left to apply!
Life science founders: ELSA by Life Science Factory is still open: don’t miss out!
Get hands-on support with coaching, market validation, pitching & investor access.
📅 Apr–Jun 2026 | 📝 Deadline: Mar 20
Apply: lifescience-factory.com/en/program-d...
Join the 5th Young Investigator Workshop at #ESCMID2026 in Munich!
🗓 Apr 19 | 🕤 09:30 CEST
🎟 Free for ticket holders + livestream
Learn, connect, and get inspired in clinical research 👇
www.ecraid.eu/articles/sig...
Did you miss the 10th AMR Conference or need a quick refresh? From bold startup ideas to tough discussions on financing innovation and the future of antimicrobial R&D, discover the key highlights from Basel.
➡️ www.incate.net/big-ideas-bo...
#AMR #AMRConference #AntimicrobialResistance
Acinetobacter baumannii remains a major healthcare threat with rising multidrug resistance and limited treatment options.
In a new @gardp.bsky.social REVIVE article, Mohamad Yasmin and Robert A. Bonomo explore the challenges and future therapies.
Read here ➡️ revive.gardp.org/managing-aci...
We are really happy to have you onboard the INCATE community, @ecraid.bsky.social ! Thank you for this recognition of our work
New @who.int publication: 3 TPPs for urgently needed antibiotics.
They guide R&D for:
- Severe MDR Gram-negative infections
- Resistant Gram-positive infections in immunosuppressed/critically ill patients
- Bacterial meningitis
Read here ➡️ www.who.int/publications...
The 2026 Antimicrobial Resistance Benchmark from the Access to Medicine Foundation provides a valuable overview of how the pharmaceutical sector is addressing AMR.
Access report here ➡️ accesstomedicinefoundation.org/news/tools-t...
AI is accelerating antibiotic discovery , but technology alone won’t solve antimicrobial resistance.
- If science is advancing, why are so few new antibiotics reaching the market?
- Who will help bridge the funding gap in antimicrobial innovation?
Read here ➡️ www.statnews.com/2026/03/05/a...
New collaboration at the AMR Conference 2026!
We’re happy to announce that @ecraid.bsky.social has joined INCATE as a supporting partner. They will support and guide our ventures, strengthening their path toward successful development of new treatment modalities to combat #AMR.
Welcome!
INCATE is at the 10th AMR Conference, come find us!
Today:
- Session “Non-traditional assets: the translation conundrum.”
at 3pm, room Sydney
- Startup Pitch Event at 6pm, room Sydney
We are at Booth #9 both days. Swing by, say hello, and let’s talk about how we move the field forward together.
The pre-AMR Conference has officially kicked off: this year we host a workshop on “Development of new P. aeruginosa interventions.”
A big thank you to @bsse.ethz.ch, to @nccr-antiresist.bsky.social and to @dzif.bsky.social.
And most importantly, thank you to all participants and speakers!
💥 Our February newsletter is out, and what a month is has been! 💥
- INCATE nominates its first CEO
- New Stage I winners
- New partnership
- All set for the AMR Conference!
- ... and more!
➡ 6s05i.r.sp1-brevo.net/mk/mr/sh/Oyc...
Haven't you subscribed yet? ➡ lnkd.in/eJ7vyBCa
🌍 Another exciting milestone for 2026!
We are proud to collaborate with the Cystic Fibrosis Foundation to accelerate innovation tackling AMR. Together, we’re supporting early-stage innovators and advancing new antibacterial solutions for the CF community.
Read more ➡️ www.incate.net/incate-and-c...